Alector Inc (ALEC) Stock Price, Quote & News

Company Profile

Alector, Inc., a late-stage clinical biotechnology company, develops therapies that is focused on counteracting the devastating progression of neurodegenerative diseases. The company's products under development include Latozinemab (AL001), an investigational human recombinant monoclonal antibody designed to elevate progranulin (PGRN), a protein encoded by the granulin (GRN) gene that regulates lysosomal function, neuronal survival, and inflammation in the brain. Its lead PGRN-elevating candidat...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 231 5660

Website: www.alector.com

Address:

131 Oyster Point Boulevard, Suite 600, South San Francisco, United States

GangsterX Jan. 12 at 5:51 PM

$ALLO $ALEC CPI data tomm.. no scare shix baby... No pain no gain

0 · Reply

revuelto Jan. 10 at 11:51 AM

$ALEC will nivisnebart work for ad? if it does, it taps a massive $10B+ market… latozinemab’s flop raises flags on the shared mechanism but different indications (rare ftd grn vs. broader ad) and optimized designs.. we’ll know more from the progress ad ph 2 interim in h1… trading at ~24-30% discount to cash today✌️

0 · Reply

DarkSonar Jan. 7 at 2:08 PM

$ALEC Fill the gap play? 🔬

0 · Reply

GangsterX Jan. 6 at 2:57 PM

$ALLO $ALEC these 2 stocks will explode. Never sell ịt Juat hold until data readout

1 · Reply

revuelto Jan. 5 at 9:12 PM

$ALEC looks like someone is quietly building a sizable position here…we should find out the reason soon✌️

0 · Reply

G101SPM Dec. 30 at 6:52 PM

#SPMNOTES HEAD'S UP! PLANNING TO TAKE *TAX LOSSES TOMORROW. $IMRN $0.73 $DV $11.60 $INDI $3.62 $ALEC $1.49 $LGVN $0.51 * For U.S. investors, the last day to sell investments to realize losses for the current tax year is December 31.

0 · Reply

AuditorAlpha Dec. 24 at 12:41 PM

$ALEC The next phase will be defined by how external catalysts materialize before balance-sheet pressure intensifies. Momentum requires evidence, not projections.

0 · Reply

SuperGreenToday Dec. 23 at 1:50 PM

$ALEC Share Price: $1.46 Contract Selected: Jul 17, 2026 $0.5 Calls Buy Zone: $0.63 – $0.77 Target Zone: $1.17 – $1.43 Potential Upside: 76% ROI Time to Expiration: 205 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

revuelto Dec. 18 at 8:06 PM

$ALEC I’m holding a very small position just in case there’s an unexpected upside catalyst…it is bullish✌️

0 · Reply

revuelto Dec. 15 at 6:30 PM

$ALEC retail behavior 101…the $1.5 and $2.5 calls expiring 12/19 look like cheap lotto bets…if they don’t expire worthless, as I expect they will, then sec, what are you doing? 😀

0 · Reply

Alector Appoints Neil Berkley as Chief Financial Officer and Chief Business Officer

Dec 8, 2025, 6:27 PM EST - 5 weeks ago

Alector, Inc. (ALEC) Presents at BofA Securities CNS Therapeutics Virtual Conference 2025 Transcript

Dec 1, 2025, 4:05 PM EST - 6 weeks ago

Alector to Participate in the Bank of America CNS Therapeutics Conference

Nov 26, 2025, 11:00 AM EST - 7 weeks ago

ALEC Investors Have Opportunity to Join Alector, Inc. Fraud Investigation with the Schall Law Firm

Nov 6, 2025, 4:05 PM EST - 2 months ago

Alector Reports Third Quarter 2025 Financial Results and Provides Business Update

Oct 22, 2025, 12:07 PM EDT - 3 months ago

Clinical Failure Halts Alector's Dementia Program, Company Reduces Workforce

Oct 21, 2025, 6:45 PM EDT - 3 months ago

Alector Announces Results from its Phase 3 Clinical Trial of Potential FTD-GRN Therapeutic

Oct 21, 2025, 6:41 PM EDT - 3 months ago

Alector shares plunge after dementia drug fails to slow disease progression

Oct 21, 2025, 4:05 PM EDT - 3 months ago

Alector Announces Topline Results from Latozinemab Phase 3 Trial in Individuals with Frontotemporal Dementia Due to a GRN Mutation and Provides Business Update

Oct 10, 2025, 4:32 AM EDT - 3 months ago

4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals

ALDX BDTX CHRS

Sep 22, 2025, 9:03 PM EDT - 4 months ago

Alector, Inc. - Special Call

Sep 16, 2025, 8:00 AM EDT - 4 months ago

Alector to Host Virtual Research and Development Event Highlighting PGRN Franchise and Brain Carrier Programs

Sep 8, 2025, 4:45 PM EDT - 4 months ago

Alector, Inc. (ALEC) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Aug 28, 2025, 8:00 AM EDT - 4 months ago

Alector to Participate in Upcoming Healthcare Conferences

Aug 9, 2025, 2:35 AM EDT - 5 months ago

Alector, Inc. (ALEC) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 5 months ago

Alector Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 31, 2025, 4:05 PM EDT - 5 months ago

Alector to Host Second Quarter and Mid-Year 2025 Earnings Conference Call

Jun 13, 2025, 4:05 PM EDT - 7 months ago

Alector Provides Executive Leadership Update

Jun 3, 2025, 8:00 AM EDT - 8 months ago

Alector to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

May 8, 2025, 4:05 PM EDT - 8 months ago

Alector Reports First Quarter 2025 Financial Results and Provides Business Update

Apr 17, 2025, 8:00 AM EDT - 9 months ago

Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer's Disease

GSK

Feb 27, 2025, 1:09 AM EST - 11 months ago

Alector, Inc. (ALEC) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 4:05 PM EST - 11 months ago

Alector Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 19, 2025, 4:05 PM EST - 11 months ago

Alector to Host Fourth Quarter and Full-Year 2024 Earnings Conference Call

Jan 13, 2025, 8:00 AM EST - 1 year ago

Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025

Dec 4, 2024, 2:20 PM EST - 1 year ago

Neurology-Focused Alector Downgraded On Failed Alzheimer's Study, BofA Securities Highlights Lack Of Catalysts

Nov 26, 2024, 10:29 AM EST - 1 year ago

Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce

Nov 25, 2024, 4:05 PM EST - 1 year ago

Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer's Disease and Provides Business Update

Nov 14, 2024, 4:05 PM EST - 1 year ago

Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital

Nov 6, 2024, 4:05 PM EST - 1 year ago

Alector Reports Third Quarter 2024 Financial Results and Provides Business Update

Aug 8, 2024, 11:53 PM EDT - 1 year ago

Alector, Inc. (ALEC) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 4:05 PM EDT - 1 year ago

Alector Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 31, 2024, 4:05 PM EDT - 1 year ago

Alector to Host Mid-Year Earnings Conference Call

Jul 28, 2024, 8:05 AM EDT - 1 year ago

Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)

Jul 23, 2024, 7:00 AM EDT - 1 year ago

Alector to Present Data on Pipeline Focus Areas at the Alzheimer's Association International Conference® (AAIC®) 2024

Jun 10, 2024, 7:00 AM EDT - 1 year ago

Alector to Host Virtual Research and Development Event Highlighting Alector Brain Carrier Blood-Brain Barrier Technology Platform

Feb 27, 2024, 11:23 PM EST - 2 years ago

Alector, Inc. (ALEC) Q4 2023 Earnings Call Transcript

Feb 27, 2024, 4:05 PM EST - 2 years ago

Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 20, 2024, 4:05 PM EST - 2 years ago

Alector to Host Fourth Quarter and Full-Year 2023 Earnings Call

Feb 8, 2024, 7:00 AM EST - 2 years ago

Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer's Disease

Feb 7, 2024, 7:00 AM EST - 2 years ago

FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)

Jan 19, 2024, 9:20 AM EST - 2 years ago

Alector Announces Closing of Public Offering

Jan 17, 2024, 5:32 PM EST - 2 years ago

Alector: Q4 2024 Data Release Could Provide Major Shift For Valuation

Jan 17, 2024, 8:54 AM EST - 2 years ago

Alector Announces Pricing of Public Offering of Common Stock

Jan 16, 2024, 4:01 PM EST - 2 years ago

Alector Announces Proposed Public Offering of Common Stock

Jan 16, 2024, 11:12 AM EST - 2 years ago

Alector: Good Data, Huge Cash, No Near Term Catalyst

Nov 28, 2023, 7:00 AM EST - 2 years ago

Alector to Host Two Virtual Research and Development Events Highlighting TREM2 and Progranulin Programs

Nov 8, 2023, 7:00 AM EST - 2 years ago

Alector to Participate in the Stifel Healthcare Conference

Nov 7, 2023, 4:05 PM EST - 2 years ago

Alector Reports Third Quarter 2023 Financial Results and Provides Business Update

GangsterX Jan. 12 at 5:51 PM

$ALLO $ALEC CPI data tomm.. no scare shix baby... No pain no gain

0 · Reply

revuelto Jan. 10 at 11:51 AM

0 · Reply

DarkSonar Jan. 7 at 2:08 PM

$ALEC Fill the gap play? 🔬

0 · Reply

GangsterX Jan. 6 at 2:57 PM

$ALLO $ALEC these 2 stocks will explode. Never sell ịt Juat hold until data readout

1 · Reply

revuelto Jan. 5 at 9:12 PM

$ALEC looks like someone is quietly building a sizable position here…we should find out the reason soon✌️

0 · Reply

G101SPM Dec. 30 at 6:52 PM

0 · Reply

AuditorAlpha Dec. 24 at 12:41 PM

$ALEC The next phase will be defined by how external catalysts materialize before balance-sheet pressure intensifies. Momentum requires evidence, not projections.

0 · Reply

SuperGreenToday Dec. 23 at 1:50 PM

0 · Reply

revuelto Dec. 18 at 8:06 PM

$ALEC I’m holding a very small position just in case there’s an unexpected upside catalyst…it is bullish✌️

0 · Reply

revuelto Dec. 15 at 6:30 PM

$ALEC retail behavior 101…the $1.5 and $2.5 calls expiring 12/19 look like cheap lotto bets…if they don’t expire worthless, as I expect they will, then sec, what are you doing? 😀

0 · Reply

Felo254 Dec. 11 at 6:46 PM

$ALEC Interesting climb here. Wonder what’s driving it 🤔

1 · Reply

Cryptojoe9 Nov. 26 at 10:48 PM

$TMC am guessing this is next $ALEC . Seeing unusual options

1 · Reply

ZacksResearch Nov. 18 at 3:43 PM

$ALEC’s 63% crash in a month — this is the kind of biotech gut-punch that forces a reset. The dementia candidate failed to slow disease progression in a late-stage study, and now the company is rolling out job cuts and shifting its pipeline strategy. Full breakdown on what’s next for ALEC 👉 https://www.zacks.com/stock/news/2792597/alector-stock-plummets-63-in-a-month-heres-what-you-need-to-know?cid=sm-stocktwits-2-2792597-teaser-21387&ADID=SYND_STOCKTWITS_TWEET_2_2792597_TEASER_21387

0 · Reply

ZacksResearch Nov. 18 at 2:43 PM

$ALEC tumbles 62.5% — what's behind the massive drop? The plunge follows the failure of its late-stage study for latozinemab in FTD-GRN patients, missing key clinical endpoints. Alector is now cutting 49% of its workforce to focus on core programs. Discover the full story and future plans here 👉 https://www.zacks.com/stock/news/2792597/alector-stock-plummets-63-in-a-month-heres-what-you-need-to-know?cid=sm-stocktwits-2-2792597-body-21383&ADID=SYND_STOCKTWITS_TWEET_2_2792597_BODY_21383

0 · Reply